Gain insights into RxSight's Q1 2025 earnings highlights, revised guidance, market challenges, and growth strategies.
Join us in Prince Albert for the Journey to Jazz Festival 2025, where music, art, and cultural reflection converge in a ...
RxSight (RXST, Financials) shares dropped 43.6% to $14.74 as of 10:28 a.m. ET on Thursday after the company cut its full-year ...
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients ...
Mount Nelson, A Belmond Hotel, Cape Town, has announced the exciting appointment of Patrick Fisher as its new General Manager ...
RxSight (RXST) stock plunged 28% as the MedTech firm cut full-year guidance and issued disappointing early Q1 results, citing ...
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected ...
Stifel lowered the firm’s price target on Bausch + Lomb (BLCO) to $15 from $17 and keeps a Hold rating on the shares. Following last week’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback